Rhodiola rosea as a traditional cardiac adaptogen: ethnomedical insights, bioactive metabolites, and multi-target mechanisms underlying its cardioprotective potential (2020–2025)

Background Cardiovascular disease remains a leading global health burden. Rhodiola rosea (RR), a botanical drug used in Tibetan, Mongolian, and Scandinavian ethnomedical traditions for cardiac fatigue and hypoxia tolerance, has been extensively studied; however, its cardioprotective potential has not been systematically summarized from an ethnopharmacological perspective. Objective This review integrates ethnomedical insights with contemporary evidence (2020–2025) to critically assess RR’s cardioprotective effects, core metabolites, and molecular mechanisms, delineating what the current evidence does and does not establish. Methods Following PRISMA 2020, PubMed, Web of Science, and CNKI were searched (January 2020–June 2025) with database-specific strategies. Evidence was appraised using an explicit hierarchy (clinical > in vivo > isolated-metabolite in vitro > extract-level in vitro > in silico ), SYRCLE and RoB 2 tools, and ConPhyMP and Four Pillars best-practice criteria. Results Of 666 records identified, 82 publications met the inclusion criteria (28 in vitro , 45 in vivo animal studies, 4 clinical studies, and 5 systematic reviews). RR’s core metabolites (salidroside, tyrosol, herbacetin, and oligomeric proanthocyanidins [OPCRR]) concurrently modulate the PI3K/Akt, Nrf2/HO-1, and AMPK/mTOR pathways; novel mechanisms include ferroptosis regulation, epigenetic modulation, and support of cardiac progenitor cell function and paracrine repair. However, the evidence is predominantly preclinical, several polyphenolic metabolites carry pan-assay interference (PAINS) liabilities, and clinical evidence remains limited to 4 small, heterogeneous studies. Conclusion RR provides a framework for bridging traditional ethnomedical use with modern pharmacology and shows multi-target cardioprotective potential across diverse preclinical models, but the current human evidence is limited and preliminary. Standardized preparations, PAINS-aware mechanistic studies, and adequately powered randomized trials are priorities for future research.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-17
DOI
https://doi.org/10.3389/fphar.2026.1944739
Primary Topic
Medicinal Plants and Bioactive Compounds
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Rhodiola rosea as a traditional cardiac adaptogen: ethnomedical insights, bioactive metabolites, and multi-target mechanisms underlying its cardioprotective potential (2020–2025)

Ke Hong, Chang Yao, Yanlei Xu, Yu Ying et al.
1 links
Frontiers in Pharmacology
Medicinal Plants and Bioactive Compounds
article

Rhodiola rosea as a traditional cardiac adaptogen: ethnomedical insights, bioactive metabolites, and multi-target mechanisms underlying its cardioprotective potential (2020–2025)

Ke Hong, Chang Yao, Yanlei Xu, Yu Ying, Cong Wang
article en

Abstract

Background Cardiovascular disease remains a leading global health burden. Rhodiola rosea (RR), a botanical drug used in Tibetan, Mongolian, and Scandinavian ethnomedical traditions for cardiac fatigue and hypoxia tolerance, has been extensively studied; however, its cardioprotective potential has not been systematically summarized from an ethnopharmacological perspective. Objective This review integrates ethnomedical insights with contemporary evidence (2020–2025) to critically assess RR’s cardioprotective effects, core metabolites, and molecular mechanisms, delineating what the current evidence does and does not establish. Methods Following PRISMA 2020, PubMed, Web of Science, and CNKI were searched (January 2020–June 2025) with database-specific strategies. Evidence was appraised using an explicit hierarchy (clinical > in vivo > isolated-metabolite in vitro > extract-level in vitro > in silico ), SYRCLE and RoB 2 tools, and ConPhyMP and Four Pillars best-practice criteria. Results Of 666 records identified, 82 publications met the inclusion criteria (28 in vitro , 45 in vivo animal studies, 4 clinical studies, and 5 systematic reviews). RR’s core metabolites (salidroside, tyrosol, herbacetin, and oligomeric proanthocyanidins [OPCRR]) concurrently modulate the PI3K/Akt, Nrf2/HO-1, and AMPK/mTOR pathways; novel mechanisms include ferroptosis regulation, epigenetic modulation, and support of cardiac progenitor cell function and paracrine repair. However, the evidence is predominantly preclinical, several polyphenolic metabolites carry pan-assay interference (PAINS) liabilities, and clinical evidence remains limited to 4 small, heterogeneous studies. Conclusion RR provides a framework for bridging traditional ethnomedical use with modern pharmacology and shows multi-target cardioprotective potential across diverse preclinical models, but the current human evidence is limited and preliminary. Standardized preparations, PAINS-aware mechanistic studies, and adequately powered randomized trials are priorities for future research.

Frontiers in PharmacologyVol. 17
Nanjing University of Chinese Medicine (CN)
Good health and well-being
Medicinal Plants and Bioactive Compounds
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon